Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
Brian M. Maas, Jos Lommerse, Nele Plock, et al.
EBioMedicine (2021) Vol. 73, pp. 103651-103651
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Natalie I Mazur, Jonne Terstappen, Ranju Baral, et al.
The Lancet Infectious Diseases (2022) Vol. 23, Iss. 1, pp. e2-e21
Open Access | Times Cited: 269
Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates
Tomer Zohar, Jeff C. Hsiao, Nickita Mehta, et al.
Cell Host & Microbe (2021) Vol. 30, Iss. 1, pp. 41-52.e5
Open Access | Times Cited: 60
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 34
The road to approved vaccines for respiratory syncytial virus
Tracy J. Ruckwardt
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 30
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults
Jia Yao Phuah, Brian M. Maas, Aimin Tang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 169, pp. 115851-115851
Open Access | Times Cited: 17
Current Antiviral Therapies and Promising Drug Candidates against Respiratory Syncytial Virus Infection
Ziheng Feng, Zhengde Xie, Lili Xu
Virologica Sinica (2025)
Open Access
Advances in development of antiviral strategies against respiratory syncytial virus
Ge Yang, Guangyu Jiang, Jian–Dong Jiang, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Structural basis for respiratory syncytial virus and human metapneumovirus neutralization
Rose Miller, Jarrod J. Mousa
Current Opinion in Virology (2023) Vol. 61, pp. 101337-101337
Closed Access | Times Cited: 10
Evaluation of a stabilized RSV pre-fusion F mRNA vaccine: Preclinical studies and Phase 1 clinical testing in healthy adults
Jesse C. Nussbaum, Xin Cao, Radha Railkar, et al.
Vaccine (2023) Vol. 41, Iss. 44, pp. 6488-6501
Closed Access | Times Cited: 9
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults
Yuji Orito, Naoyuki Otani, Yuki Matsumoto, et al.
Clinical and Translational Science (2022) Vol. 15, Iss. 7, pp. 1753-1763
Open Access | Times Cited: 14
Virus neutralization assays for human respiratory syncytial virus using airway organoids
Laura L.A. van Dijk, Laurine C. Rijsbergen, Bruno Tello Rubio, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies
Julia Dvorkin, Julián De Luca, Damián Álvarez-Paggi, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 595-605
Open Access | Times Cited: 7
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
Shaun O’Hagan, Niamh Galway, Michael D. Shields, et al.
Drug Healthcare and Patient Safety (2023) Vol. Volume 15, pp. 103-112
Open Access | Times Cited: 7
Current state and challenges in respiratory syncytial virus drug discovery and development
Gang Zou, Sushan Cao, Zhao Gao, et al.
Antiviral Research (2023) Vol. 221, pp. 105791-105791
Closed Access | Times Cited: 7
Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections
Jim Boonyaratanakornkit, Michael Boeckh, Alpana Waghmare
Current Opinion in Infectious Diseases (2022) Vol. 35, Iss. 4, pp. 280-287
Closed Access | Times Cited: 11
RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
Deidre Wilkins, Ulrika Wählby Hamrén, Yue Chang, et al.
PEDIATRICS (2024) Vol. 154, Iss. 5
Closed Access | Times Cited: 1
A Phase 1b/2a Single Ascending Dose Study of a Half-life Extended RSV Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants
Shabir A. Madhi, Eric A. F. Simões, Armando Acevedo, et al.
The Journal of Infectious Diseases (2024)
Open Access | Times Cited: 1
Antibodies face the challenge against human respiratory syncytial virus
Rory D. de Vries, Rik L. de Swart
Cell Host & Microbe (2023) Vol. 31, Iss. 1, pp. 135-136
Open Access | Times Cited: 4
Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach
Bhargava Kandala, Nele Plock, Akshita Chawla, et al.
EBioMedicine (2022) Vol. 84, pp. 104264-104264
Open Access | Times Cited: 7
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants
Nicola Principi, Giovanni Autore, Serafina Perrone, et al.
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 6, pp. 747-762
Closed Access | Times Cited: 3
Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration
Elizabeth R. Packnett, Isabelle Winer, Abiola Oladapo, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 3
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
Kevin M. Tuffy, Bahar Ahani, Anastasia A. Aksyuk, et al.
The Journal of Infectious Diseases (2023) Vol. 228, Iss. 8, pp. 1055-1059
Open Access | Times Cited: 2
Immunization with a mucosal, post-fusion F/G protein-based polyanhydride nanovaccine protects neonatal calves against BRSV infection
Teresia Maina, Elizabeth A. Grego, Scott Broderick, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Phage-derived anti-idiotype and anti-YTE antibodies in development of MK-1654 pharmacokinetic and immune response assays
April Li, Michael D. Swanson, Nicole Sullivan, et al.
Bioanalysis (2023) Vol. 15, Iss. 16, pp. 1049-1067
Closed Access | Times Cited: 2
A Quantitative Clinical Pharmacology-Based Framework For Model-Informed Vaccine Development
Rajat Desikan, Massimiliano Germani, Piet H. van der Graaf, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 1, pp. 22-32
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top